DeciBio

Exciting insights from BioLoomics' CEO, Dr. Doug Chapnick! Discover how BioLoomics is revolutionizing antibody-drug conjugates (ADCs) for better cancer treatment, leveraging AI, and enhancing their scientific leadership with the new CSO, Kurt Gish. Dive into the full Q&A for a closer look at their groundbreaking work and future plans. Read more: https://lnkd.in/gtShxKin Interested in diving deeper into the #ADC space and staying updated on the latest developments? Discover how DeciBio's ADC Tracker, TheraTrack, keeps you informed about all ADCs in development: https://lnkd.in/ezagQihr Reach out to Joe Daccache, Ph.D. directly to learn more. We're passionate about advancing the field of targeted therapeutics and would love to discuss how DeciBio can support your journey! #Biotech #antibodies #AI

The Spatial Biology market has been evolving at a rapid pace, spurred on by excitement in the technology and a strong competitive landscape. We’ve outlined a few of the key market dynamics that influenced the market’s growth over the last year. Curious to get deeper insights into how the market is expected to evolve over the next 5 years? Check out our website to download a sample of our Spatial Biology Market Report, which features insights from our research with >80 spatial biology stakeholders: https://lnkd.in/gwhtwZhj #spatialbiology #marketreport #competitivelandscape

So much movement has happened in the oncology liquid biopsy market in the first six months of 2024. We've captured that and more in our third edition of the Oncology LBx Market Report. With updated content around the following (and not limited to): - Market sizing, segmentation, and forecast - Our internal database of LBx companies and their offerings, evaluated the latest performance data from key players - Incorporated the latest trends in the LBx market, based on interviews with experts and secondary research - Assessed new / current offerings and expected future portfolio developments - Evaluated emerging, high-growth applications in depth, elucidating both quantitative and qualitative market divers, moderators, and trends: (MRD, monitoring, early detection) - Developed deep-dive profiles of select key competitors Want to be notified when it's available? Sign up here: https://lnkd.in/euT9db7K #LiquidBiopsy #Oncology #PrecisionMedicine

May was a productive month for #LBx, with significant clinical and regulatory updates in particular.     Clinical and Regulatory  Guardant Health's blood test for CRC screening, Shield, received FDA Medical Devices Advisory Committee recommendation, paving the way for potential approval. The UK NHS will not be accelerating implementation of GRAIL's Galleri multi-cancer early detection test based on data from the first year of their ongoing clinical study, finding the data insufficient to justify a large-scale pilot at this time. Guardant Health's Guardant360 CDx blood test received EU IVDR certification for tumor profiling in solid cancers and identifying patients eligible for specific targeted therapies in lung and breast cancer. Mercy BioAnalytics, Inc. received an FDA BDD for it’s Halo Ovarian Cancer Screening Test of extracellular vesicles in asymptomatic, postmenopausal women. In Japan, 中外製薬 / Chugai Pharmaceutical Co., Ltd. announced approval from the Ministry of Health, Labour and Welfare for FoundationOne Liquid CDx to be used in the detection of copy number alterations and blood-based tumor mutational burden.    Company Announcements & Product Launches  ANGLE, a UK LBx company, partnered with AstraZeneca to develop a CTC-based Androgen Receptor assay for prostate cancer studies. OSF HealthCare is partnering with DELFI Diagnostics to use DELFI's blood test, FirstLook Lung, to improve lung cancer screening rates. Oxford BioDynamics Plc is partnering with King's College London to develop a blood test using Oxford's EpiSwitch platform to identify people at high risk of rheumatoid arthritis following the successful APIPPRA trial.    Clinical Trials & Study Results  In a study published in The Journal of Heart and Lung Transplantation , sponsored by CareDx, Inc., the combination of gene expression profiling and donor-derived cell-free DNA analysis was found to be a better indicator of acute cellular rejection following heart transplantation, compared to the use of either test on its own. Researchers from BostonGene developed a framework for immunoprofiling using blood samples and flow cytometry. These immune profiles can be associated with therapy response and may be useful in informing therapy decisions.    M&A | VC | Private Equity | Legal  Phenomix Sciences, spun out of Mayo Clinic, closed a $5.5 M Series A funding round to advance their blood test, MyPhenome, aimed at identifying obesity phenotypes to personalize weight loss treatment approaches. This test will be validated in a clinical trial funded by a $2.3 M NIH grant.    Read the newsletter for more:  https://lnkd.in/gTWfx_hw   Sign up to receive our Liquid Biopsy Newsletter in your email: https://lnkd.in/gKQn7_zp   The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad     #earlydetection #productlaunches

Our NGS #DxBooks are updated quarterly with new insights into changes in the sequencing competitive landscape. Using our proprietary licensable data, our NGS Dx Books expert Rishikesh Kayathi conducted an analysis comparing Illumina and Thermo Fisher Scientific platforms and assays in clinical #oncology and observed three notable trends since last year: Diversity and Dominance in Gene Panels Illumina leads in panel diversity and volume, leveraging an expansive range of third-party kits. Our data visualizes this dominance across various panel sizes including WES and WGS, and the impressive traction these approaches have gained in recent years. Regional Dynamics and Market Shares While ThermoFisher has carved a niche in smaller gene panels (1-52 genes), especially in Europe, Illumina continues to expand its footprint in larger panels, with a dominant position in the U.S. Strategic Positions in a Competitive Field Despite challenges in the stock market, Illumina's strategic partnerships with reagent and bioinformatics firms like Pillar Biosciences Incorporated and Velsera has solidified its entrenched market position, simplifying workflows and enhancing user experiences. Conversely, ThermoFisher’s investment in an integrated ecosystem with solutions like Ion Chef and Ion Reporter caters to labs seeking end-to-end automation. Interested in deeper dive? Request a demo or sample of our data here: https://lnkd.in/e-w5Q5HX

Live from Lithuania with our principal, Katie Maloney, at the #ECDP meeting, where she is engaging with European digital pathology stakeholders to discuss emerging tools and technologies. Europe leads the US in clinical DP adoption, so speaking with the pathologists and companies enabling this utilization has been great. If you couldn't attend the conference, be sure to explore our Digital Pathology Market Report here: https://lnkd.in/dxxw_hTt #ECDP24 #DigitalPathology

That’s a wrap on this year’s ASCO24. Fresh from the windy city, our team members Andrew Aijian, Megan Nacar, and Tina Wang share their key observations from liquid biopsy dominance to the continued rise of multimodal approaches. Explore the carousel for our key observations from ASCO 2024. What did you think of this year's ASCO? We'd love to hear your thoughts—comment below or reach out to us directly to continue the conversation! #ASCO2024 #LiquidBiopsy #Epigenomics #Radiomics #PrecisionMedicine

Last week, our Founding Partner, Stephane Budel, joined a webinar with McDermott Will & Emery and McDermott+Consulting to discuss the impacts of the FDA's new LDT rule. The carousel below, created in collaboration with Maximilian Schmid, M.D., summarizes the panel discussion and adds our DeciBio insights. Watch the full webinar here: https://lnkd.in/ghmjJJes The Key Takeaway - FDA LDT Rule: Mixed Bag, Net Negative Enhanced Safety but at a Cost: Stricter standards aim to improve patient safety but disproportionately affect small firms and startups. Investment Impact: Heightened regulatory risks may deter investors, reducing sector investment. Innovation Slowdown: Increased regulatory burden may delay new diagnostic technologies. For more insights, check the carousel. Let's discuss—comment below or reach out to us directly! #FDA #LDT #Diagnostics #Innovation #PrecisionMedicine

2024 has delivered exciting and impactful regulatory updates, product approvals, funding, and M&A activity in digital health. At the end of 2023, the FDA established a new advisory committee on digital health technologies to inform how to best leverage these tools to improve patient outcomes. Q1 2024 saw initiatives from the White House establishing AI governance in healthcare, and establishing funds to leverage AI / imaging, diagnostics tools, and devices for innovation and research in women’s health. The FDA also provided an update regarding medical device premarket approval (PMA) safeguard requirements. AI / Imaging saw several regulatory approvals, funding, and partnerships. Notably, NVIDIA is working with Johnson & Johnson MedTech to bring new AI capabilities to the company’s digital surgery ecosystem, and Hologic, Inc.’s digital cytology platform was granted marketing authorization by the FDA. In Disease Management / Digital Therapeutics, Dexcom’s over-the-counter glucose monitor was cleared by the FDA, and several new partnerships have either launched or expanded, deepening key players’ digital health offerings. Women’s Health / Femtech saw exciting developments, with FDA clearance granted to GE HealthCare’s Novii+ wireless maternal / fetal monitoring solution, and Oova’s launch of its at-home Perimenopause Hormone Kit, complete with urine-based, multi-hormone biomarkers (e.g., estrogen / E3G) and an app with real-time data tracking. Finally, there were significant regulatory approvals, funding, and product launches in Informatics / Healthcare IT Solutions, in addition to new partnerships such as Pieces Technologies’ integration with Amazon Web Services (AWS) to support their EHR-enhancing AI platform. Check out our newsletter to learn more about these developments in digital health: https://lnkd.in/ggcpzwnY Sign up to receive updates directly into your inbox: https://lnkd.in/gKQn7_zp These headlines were curated by Olivia Qiu, Katherine Erickson, Katie Schneider, and Kevin Xu. #digitalhealth #healthcareinnovation #ai

May was an exciting month for the next-generation therapeutics field. Regulatory approvals and updates were a main focus in the Cell Therapy space during May. Be Biopharma announced FDA clearance of their IND application for BE-101 in Hemophilia B, while Bristol Myers Squibb received FDA approval for Breyanzi in Mantle Cell Lymphoma and the FDA released a new draft guidance on safety testing for cell therapies. In the ADC space, Almac Discovery nominated a first-in-class bispecific ADC for refractory lung cancer, SixPeaks Bio AG made their debut with $100M in funding, and IDT Australia Limited received a government grant to build Australia’s first ADC manufacturing facility.   In the Gene Therapy space, PTC Therapeutics, Inc. announced the FDA accepted its BLA for Upstaza, while Sarepta Therapeutics indicated the FDA may release a decision on Elevidys sooner than expected. Freeline Therapeutics announced new clinical data for their AAV gene therapy for Gaucher disease and Pfizer announced a death in the DAYLIGHT study with their candidate for Duchenne muscular dystrophy. In the Oligo Therapy space, Twist Bioscience introduced multiplexed gene fragments for high-throughput screening applications and Takara Bio USA, Inc. launched PrimeCap T7 RNA Polymerase for mRNA vaccine development.   Read on to see additional developments that occurred in May here: https://lnkd.in/g2stsNAa Subscribe to our newsletter on Linkedin: https://lnkd.in/gMfy6_YZ Sign up to receive our Next-Generation Therapeutics Newsletter in your email: https://lnkd.in/gKQn7_zp These headlines were curated by Rebecca Burnham, PhD, Joe Daccache, Ph.D., Luka Jelcic, Juilee Malavade, Ph.D., and Carl Schoellhammer. #nextgenerationtherapeutics #celltherapy #genetherapy #oligotherapy #adcs